Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406396 | 0.84 | DRD2 (0.38) | DRD2DRD4DRD3SLC6A4LMNA | |
| SCHEMBL2410211 | 0.76 | SCN4A (0.32) | SCN4A | |
| SCHEMBL2405725 | 0.71 | DRD2 (0.39) | DRD2DRD4DRD3HTR2ASLC6A4 | |
| SCHEMBL2408055 | 0.70 | CYP3A4 (0.38) | DRD2DRD4DRD3HTR2ASLC6A4 | |
| SCHEMBL1555332 | 0.68 | NOS2 (0.38) | HTR2ASLC6A4LMNASMN1; SMN2POLB | |
| SCHEMBL2408644 | 0.68 | SCN4A (0.42) | DRD2DRD4DRD3SLC6A4LMNA | |
| SCHEMBL5381054 | 0.68 | IDO1 (0.37) | DRD2DRD4DRD3HTR2ASLC6A4 | |
| SCHEMBL1555334 | 0.66 | NOS2 (0.43) | DRD2DRD4DRD3SLC6A4LMNA | |
| SCHEMBL5381052 | 0.66 | CYP3A4 (0.38) | LMNASMN1; SMN2SCN4A | |
| SCHEMBL29116273 | 0.66 | DRD2 (0.43) | DRD2DRD4DRD3HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | DRD2 3904/4885DRD4 4304/4885DRD3 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.